Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.32 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 2/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.31 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2737290 | 0.79 | ALDH1A1 (0.46) | GRM5EGLN2 | |
| SCHEMBL888963 | 0.76 | EGLN1 (0.38) | GRM5CHRNA7 | |
| SCHEMBL23250806 | 0.75 | GRM5 (0.50) | GRM5 | |
| SCHEMBL17970841 | 0.73 | HDAC8 (0.34) | HDAC8 | |
| SCHEMBL24897503 | 0.72 | CYP2C9 (0.32) | ESR1ESR2 | |
| SCHEMBL24838450 | 0.72 | PARP1 (0.31) | — | |
| SCHEMBL24838385 | 0.72 | PARP1 (0.31) | — | |
| SCHEMBL503236 | 0.71 | — | — | |
| SCHEMBL19116223 | 0.71 | APP (0.49) | GRM5 | |
| SCHEMBL21326764 | 0.71 | ACACB (0.49) | GRM5CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117658947-A | 5- (substituted aryl) -1,2, 5-thiadiazolin-3-one compounds with protein tyrosine phosphatase inhibiting effect | 杭州中美华东制药有限公司 | 2024-03-08 | — | — | CN | disclosed |
| US-20230250129-A1 | NEUROACTIVE STEROIDS AND COMPOSITIONS THEREOF | SAGE THERAPEUTICS, INC. | 2023-08-10 | — | — | US | disclosed |
| US-RE46630-E1 | Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity | BOEHRINGER INGELHELHEIM INTERNATIONAL GMBH (DE) | 2017-12-12 | — | — | US | disclosed |
| US-20160130275-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. | 2016-05-12 | — | — | US | disclosed |
| US-9102624-B2 | Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | 2015-08-11 | — | — | US | disclosed |
| US-8883779-B2 | Oxazine derivatives and a pharmaceutical composition for inhibiting BACE1 containing them | SHINOGI & CO., LTD. (JP) | 2014-11-11 | — | — | US | disclosed |
| US-20140057916-A1 | SUBSTITUTED 4-PYRIDONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-27 | — | — | US | disclosed |
| US-20140051691-A1 | OXAZINE DERIVATIVES AND A PHARMACEUTICAL COMPOSITION FOR INHIBITING BACE1 CONTAINING THEM | SHIONOGI & CO., LTD. (JP) | 2014-02-20 | — | — | US | disclosed |
| US-20130165473-A1 | Azaquinolinone Derivatives and Uses Thereof | ASTRAZENECA AB (SE) | 2013-06-27 | — | — | US | disclosed |
| US-20130071415-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2013-03-21 | — | — | US | disclosed |
| US-8343996-B2 | Azaquinolinone derivatives and uses thereof | ASTRAZENECA AB (SE) | 2013-01-01 | — | — | US | disclosed |
| US-20120003215-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2012-01-05 | — | — | US | disclosed |
| US-20100130540-A1 | AZAQUINOLINONE DERIVATIVES AND USES THEREOF | LINK MEDICINE CORPORATION (US) | 2010-05-27 | — | — | US | disclosed |
| US-20100130540-A1 | AZAQUINOLINONE DERIVATIVES AND USES THEREOF | LINK MEDICINE CORPORATION (US) | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130540-A1 | AZAQUINOLINONE DERIVATIVES AND USES THEREOF | TPMT, AZI2, NNMT | HDAC8 11/4885GRM5 458/4885CHRNA7 574/4885 |
| US-20130165473-A1 | Azaquinolinone Derivatives and Uses Thereof | TPMT, AZI2, NNMT | HDAC8 11/4885GRM5 458/4885CHRNA7 574/4885 |
| US-20120003215-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | TYMP, ZC3HAV1, TYMS | HDAC8 3221/4885GRM5 2424/4885CHRNA7 4447/4885 |
| US-20230250129-A1 | NEUROACTIVE STEROIDS AND COMPOSITIONS THEREOF | MC2R, NR3C2, AVPR1B | HDAC8 2829/4885GRM5 105/4885CHRNA7 36/4885 |
| US-20160130275-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | TYMP, ZC3HAV1, TYMS | HDAC8 3221/4885GRM5 2424/4885CHRNA7 4447/4885 |
| US-20130071415-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | JAK2, JAK1, JAK3 | HDAC8 743/4885GRM5 2971/4885CHRNA7 4860/4885 |
| US-20140057916-A1 | SUBSTITUTED 4-PYRIDONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY | SERPINB1, ELANE, SERPINB6 | HDAC8 2388/4885GRM5 3825/4885CHRNA7 3289/4885 |
| US-20140051691-A1 | OXAZINE DERIVATIVES AND A PHARMACEUTICAL COMPOSITION FOR INHIBITING BACE1 CONTAINING THEM | BACE1, BACE2, APP | HDAC8 1020/4885GRM5 777/4885CHRNA7 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.